Randomized, controlled, open-label and multicentric.97 IMV patients who had severe sepsis or septic shock and ALI.Two groups: one receiving therapy with CytoSorb® hemoperfusion for 6 h per day for up to 7 consecutive days, and the other group receiving no hemoperfusion.Significant elimination of IL-6, ranging from 5% to 18% per blood pass throughout the entire treatment period. However, they did not observe any statistically significant differences in the secondary outcomes, such as the multiple organ dysfunction score, ventilation time, and time course of oxygenation. This evidence concerns the gene IL6 and acute respiratory distress syndrome.